Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records

Nazario D. Rivera-Chaparro; Jessica Ericson; Huali Wu; P. Brian Smith; Reese H. Clark; Daniel K. Benjamin; Michael Cohen-Wolkowiez; Rachel G. Greenberg

doi:10.1097/INF.0000000000002045

Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records

Nazario D. Rivera-Chaparro
, Jessica Ericson
, Huali Wu
, P. Brian Smith
, Reese H. Clark
, Daniel K. Benjamin
, Michael Cohen-Wolkowiez
, Rachel G. Greenberg

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

Original language	English (US)
Pages (from-to)	e26-e28
Journal	Pediatric Infectious Disease Journal
Volume	38
Issue number	2
DOIs	https://doi.org/10.1097/INF.0000000000002045
State	Published - Feb 1 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

Access to Document

10.1097/INF.0000000000002045

Cite this

Rivera-Chaparro, N. D., Ericson, J., Wu, H., Smith, P. B., Clark, R. H., Benjamin, D. K., Cohen-Wolkowiez, M., & Greenberg, R. G. (2019). Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records. Pediatric Infectious Disease Journal, 38(2), e26-e28. https://doi.org/10.1097/INF.0000000000002045

@article{c10885ed71f9428183bea9a50cc7482a,

title = "Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records",

abstract = "Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.",

author = "Rivera-Chaparro, \{Nazario D.\} and Jessica Ericson and Huali Wu and Smith, \{P. Brian\} and Clark, \{Reese H.\} and Benjamin, \{Daniel K.\} and Michael Cohen-Wolkowiez and Greenberg, \{Rachel G.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Wolters Kluwer Health, Inc.",

year = "2019",

month = feb,

day = "1",

doi = "10.1097/INF.0000000000002045",

language = "English (US)",

volume = "38",

pages = "e26--e28",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

Rivera-Chaparro, ND, Ericson, J, Wu, H, Smith, PB, Clark, RH, Benjamin, DK, Cohen-Wolkowiez, M & Greenberg, RG 2019, 'Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records', Pediatric Infectious Disease Journal, vol. 38, no. 2, pp. e26-e28. https://doi.org/10.1097/INF.0000000000002045

TY - JOUR

T1 - Safety, effectiveness and exposure-response of micafungin in infants

T2 - Application of an established pharmacokinetics model to electronic health records

AU - Rivera-Chaparro, Nazario D.

AU - Ericson, Jessica

AU - Wu, Huali

AU - Smith, P. Brian

AU - Clark, Reese H.

AU - Benjamin, Daniel K.

AU - Cohen-Wolkowiez, Michael

AU - Greenberg, Rachel G.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

AB - Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

UR - https://www.scopus.com/pages/publications/85059883824

UR - https://www.scopus.com/pages/publications/85059883824#tab=citedBy

U2 - 10.1097/INF.0000000000002045

DO - 10.1097/INF.0000000000002045

M3 - Article

C2 - 29601453

AN - SCOPUS:85059883824

SN - 0891-3668

VL - 38

SP - e26-e28

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 2

ER -

Safety, effectiveness and exposure-response of micafungin in infants: Application of an established pharmacokinetics model to electronic health records

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this